New developments in the treatment of systemic lupus erythematosus

Pediatric Nephrology

Volumn 27, Issue 5, 2012, Pages 727-732

  Tullus, Kjell ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Belimumab; Drug treatment; Lupus; Mycophenolate mofetil; Nephritis; Rituximab; SLE

Indexed keywords

ABATACEPT; ABETIMUS; ATACICEPT; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FORIGERIMOD; INFLIXIMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOCILIZUMAB;

BRAIN LYMPHOMA; CLINICAL TRIAL (TOPIC); DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; HUMAN; IMMUNOTHERAPY; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CHILD; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID;

EID: 84863431933     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1859-0     Document Type: Review

References (30)

1. Zetterstrom R, Berglund G (1956) Systemic lupus erythematosus in childhood; a clinical study. Acta Paediatr 45:189-204
2. Cameron JS (1994) Lupus nephritis in childhood and adolescence. Pediatr Nephrol 8:230-249 (Pubitemid 24092266)
3. Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E (2002) Long-term follow-up of childhood lupus nephritis. J Rheumatol 29:2635-2642 (Pubitemid 35416975)
4. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156-1162
5. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971-980 (Pubitemid 38269274)
6. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103-1112
7. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62:211-221
8. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N (2010) Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology (Oxford) 49:128-140
9. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB (2010) Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 77:152-160
10. Wofsy D, Appel GB, Dooley M, Ginzler E, Isenberg D, Jayne D, Salomon NLL, for the ALMS Study Group (2010) Aspreva lupus management study (ALMS) maintenance results. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24-27, Poster PO2 E23
11. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon GE, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69:2083-2089
12. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS (2011) Mycophenolate mofetil for induction treatment of lupus nephritis: A systematic review and metaanalysis. J Rheumatol 38:69-78
13. Kazyra I, Pilkington C, Marks SD, Tullus K (2010) Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 95:1059-1061
14. Marks SD, Tullus K (2010) Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 99:967-974
15. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222-233
16. Furie R, Looney J, Rovin B, Latinis K, Appel G, Sanchez-Guerrero J, Fervenza F, Maciuca R, Zhang D, Garg J, Brunetta P, and the LUNAR study group (2010) Efficacy and safety of rituximab in patients with proliferative lupus nephritis: Results from the randomized, double-blind phase III LUNAR study. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24-27, Poster PO2 E 6
17. Furie R, Rovin B, Appel G, Kamen D, Fervenza F, Spindler A, Maciuca R, Garg J, Brunetta P, and the LUNAR study group (2010) Effect of rituximab on anti-double-stranded DNA antibody and C3 levels and relationship to response: Results from the LUNAR trial. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24-27, Poster PO2 E 22
18. Mysler E, Spindler A, Guzman R, Bijl M, Jayne D, Furie R, Maciuca R, Drappa J, Shahdad S, Close D (2010) Study design and baseline patient characteristics of BELONG, the randomized double-blind, placebo-controlled phase III trial of ocrelizumab, a humanized anti-CD20 antibody, in lupus nephritis. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24-27, Poster PO2 E 20
19. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebocontrolled, phase 3 trial. Lancet 377:721-731
20. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168-1178
21. Petri M, Wallace D, Furie R, Merrill J, Ginzler E, StohlW, Chatham W, McCune J, Weinstein A, Klein J, Zhong Z, Freimuth W, for the LBSL02/99 study group (2010) Five-year experience with Belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24-27, Poster PO2 E
22. Furie R (2010) Belimumab, a BlyS-specific inhibitor, reduced disease activity and severe flares in patients with seropositive SLE: BLISS-76 Study. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24-27
23. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74
24. Press release, UCB, Rome 16th 2010; www.ucb.com/-up/ucb-com-news/ document. Accessed 10 Nov 2010
25. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18:547-555
26. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD (2008) Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial. Arthritis Rheum 58:2470-2480
27. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS (2009) Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: Long-term follow-up of 13 patients. Rheumatology (Oxford) 48:1451-1454
28. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE (2010) Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542-552
29. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P (2010) The efficacy and safety of abatacept in patients with non-lifethreatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:3077-3087
30. D'Andrea D, Xie F, Zimmer R (2010) A randomized, doubleblind, placebo-controlled study of spliceosomal peptide rigerimod in patients with systemic lupus erythematosus (SLE). 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24-27, Poster PO2 E